Amphastar Pharmaceuticals (AMPH) Projected to Post Earnings on Wednesday

Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) will likely be posting its Q1 2025 earnings data after the market closes on Wednesday, May 7th. Analysts expect Amphastar Pharmaceuticals to post earnings of $0.66 per share and revenue of $173.29 million for the quarter.

Amphastar Pharmaceuticals Price Performance

Shares of Amphastar Pharmaceuticals stock traded down $1.27 during midday trading on Tuesday, hitting $23.85. 751,786 shares of the company were exchanged, compared to its average volume of 470,026. The firm has a 50 day simple moving average of $26.19 and a 200-day simple moving average of $35.38. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.43 and a quick ratio of 2.61. The firm has a market cap of $1.13 billion, a P/E ratio of 7.95, a PEG ratio of 2.19 and a beta of 0.78. Amphastar Pharmaceuticals has a 52 week low of $22.64 and a 52 week high of $53.96.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Piper Sandler reduced their target price on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating on the stock in a research note on Friday, March 21st. Needham & Company LLC restated a "hold" rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, April 10th.

Insider Buying and Selling at Amphastar Pharmaceuticals

In other news, CFO William J. Peters sold 4,231 shares of the firm's stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total value of $116,521.74. Following the completion of the sale, the chief financial officer now directly owns 97,363 shares in the company, valued at approximately $2,681,377.02. This trade represents a 4.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. In the last quarter, insiders sold 5,231 shares of company stock worth $142,752. 27.10% of the stock is currently owned by insiders.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.